Lineage Cell Therapeutics Inc (NYSE American:LCTX)

1.19
Delayed Data
As of Sep 25
 +0.01 / +0.85%
Today’s Change
1.02
Today|||52-Week Range
1.58
+1.71%
Year-to-Date

Stock Price Forecast

The 6 analysts offering 12-month price forecasts for Lineage Cell Therapeutics Inc have a median target of 5.50, with a high estimate of 7.00 and a low estimate of 4.00. The median estimate represents a +362.18% increase from the last price of 1.19.

Analyst Recommendations

The current consensus among 7 polled investment analysts is to Buy stock in Lineage Cell Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past
months for detail

 
 
 
 
 
 
 
 

Earnings and Sales Forecasts

Current Quarter

Earnings per Share
-$0.05
Sales
$1.9M
Reporting Date
Nov 09

Earnings per Share

Move your mouse over a quarter or year to see how estimates have changed over time.

Growthquarterly -66.67%
 
 
 
 
 
 
Growthannually -16.19%
 
 
 
 
 
 

Sales

Growthquarterly -39.83%
 
 
 
 
 
 
Growthannually -32.15%
 
 
 
 
 
 
Key to the earnings and sales forecast charts.